Detalhe da pesquisa
1.
Carfilzomib-associated thrombotic microangiopathy: clinical features and outcomes.
Nephrol Dial Transplant
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38658194
2.
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
Blood
; 137(6): 733-742, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33150928
3.
Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.
Blood
; 134(24): 2209-2217, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31530564
4.
Oral therapy adherence and satisfaction in patients with multiple myeloma.
Ann Hematol
; 100(7): 1803-1813, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33938996
5.
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.
Blood
; 132(20): 2143-2153, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30201758
6.
Factors related to the outcome of prophylactic platelet transfusions in patients with hematologic malignancies: an observational study.
Transfusion
; 58(6): 1377-1387, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29542122
7.
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
EJHaem
; 5(1): 55-60, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38406520
8.
Immune-mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure.
Res Pract Thromb Haemost
; 6(4): e12702, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35599703